With over 20 years of leadership experience in the technology and life sciences sectors, Karl has successfully led complex EPCM projects across EMEA. His expertise in project execution, operational ...
Pheiron and Ribo are excited to announce that the first two strategic collaboration milestones have been successfully ...
The agency formulated its advice to manufacturers after coordinating with the CDC and Defense Department. An advisory meeting ...
President Trump’s nominee to run the FDA secured the Senate HELP Committee’s backing. Elsewhere, Sutro cut jobs and a cell ...
While initial study results suggest Beam's technology can correct alpha-1 antitrypsin deficiency's genetic roots, shares fell ...
The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched ...
The merger will give the combined entity the financial flexibility to pursue drug licensing deals and broaden its therapeutic ...
A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...
Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a ...
The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly ...
Funded by investors such as Flagship and General Catalyst, the AI startup claims its platform will help scientists speed up ...
Industry insiders are pushing to fix the small molecule ‘penalty’ by setting their hopes on a Republican majority.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback